JP2023182691A5 - - Google Patents

Info

Publication number
JP2023182691A5
JP2023182691A5 JP2023169177A JP2023169177A JP2023182691A5 JP 2023182691 A5 JP2023182691 A5 JP 2023182691A5 JP 2023169177 A JP2023169177 A JP 2023169177A JP 2023169177 A JP2023169177 A JP 2023169177A JP 2023182691 A5 JP2023182691 A5 JP 2023182691A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023169177A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023182691A (ja
Filing date
Publication date
Priority claimed from PCT/US2018/047286 external-priority patent/WO2019040471A1/en
Application filed filed Critical
Publication of JP2023182691A publication Critical patent/JP2023182691A/ja
Publication of JP2023182691A5 publication Critical patent/JP2023182691A5/ja
Pending legal-status Critical Current

Links

JP2023169177A 2017-08-22 2023-09-29 グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 Pending JP2023182691A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762548632P 2017-08-22 2017-08-22
US62/548,632 2017-08-22
PCT/US2018/047286 WO2019040471A1 (en) 2017-08-22 2018-08-21 METHODS OF TREATING UREA CYCLE DISORDERS BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING
JP2020511375A JP7781519B2 (ja) 2017-08-22 2018-08-21 グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020511375A Division JP7781519B2 (ja) 2017-08-22 2018-08-21 グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法

Publications (2)

Publication Number Publication Date
JP2023182691A JP2023182691A (ja) 2023-12-26
JP2023182691A5 true JP2023182691A5 (https=) 2026-01-29

Family

ID=63638351

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020511375A Active JP7781519B2 (ja) 2017-08-22 2018-08-21 グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法
JP2023169177A Pending JP2023182691A (ja) 2017-08-22 2023-09-29 グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020511375A Active JP7781519B2 (ja) 2017-08-22 2018-08-21 グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法

Country Status (6)

Country Link
US (2) US12139546B2 (https=)
EP (1) EP3672620A1 (https=)
JP (2) JP7781519B2 (https=)
CA (1) CA3071387A1 (https=)
MX (2) MX2020002057A (https=)
WO (1) WO2019040471A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020210642A1 (en) * 2019-04-10 2020-10-15 Camp4 Therapeutics Corporation Methods and compositions for treating urea cycle disorders
CA3205005A1 (en) * 2020-12-16 2022-06-23 Rush University Medical Center Administration of glycerol tribenzoate and glycerol phenylbutyrate for treatment of neurodegenerative and urea cycle disorders
KR20240126870A (ko) 2021-12-22 2024-08-21 캠프4 테라퓨틱스 코포레이션 조절 rna들을 표적으로 하는 안티센스 올리고뉴클레오티드를 사용한 유전자 전사의 조절

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5836308B2 (ja) 1977-02-10 1983-08-08 大塚製薬株式会社 抗体の製造方法
US4206199A (en) 1977-07-22 1980-06-03 Takeda Chemical Industries, Ltd. Novel glucagon fragment and its derivatives
JPS56163456A (en) 1980-05-21 1981-12-16 Otsuka Pharmaceut Co Ltd Preparation of antigen
US4423034A (en) 1980-10-16 1983-12-27 Toyo Jozo Kabushiki Kaisha Process for the preparation of antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
HU219674B (hu) 1992-08-28 2001-06-28 Novo Nordisk A/S Glukagon-receptort kódoló DNS-molekulák, glukagon-receptor peptidek, glukagon-receptort blokkoló monoklonális ellenanyagok, és eljárások előállításukra
JP2729159B2 (ja) 1994-10-31 1998-03-18 日清製粉株式会社 ヒトグリセンチンのモノクローナル抗体、この抗体を産生するハイブリドーマおよびそれを用いるヒトグリセンチンの定量法
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
CA2547785A1 (en) 2003-12-19 2005-07-21 Merck & Co., Inc. Cyclic guanidines, compositions containing such compounds and methods of use
NZ551405A (en) 2004-06-04 2009-06-26 Merck & Co Inc Pyrazole derivatives, compositions containing such compounds and methods of use
DE102004028862A1 (de) 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
CN1980665A (zh) 2004-07-07 2007-06-13 默克公司 吡唑酰胺衍生物，包含这些化合物的组合物和使用方法
WO2006014618A2 (en) 2004-07-22 2006-02-09 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
ES2332470T3 (es) 2005-02-11 2010-02-05 Eli Lilly And Company Derivados de tiofeno sustituidos como antagonistas del receptor de glucagon, preparacion y usos terapeuticos.
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
JP2008534593A (ja) 2005-03-30 2008-08-28 メルク エンド カムパニー インコーポレーテッド グルカゴン受容体アンタゴニスト化合物、そのような化合物を含む組成物、及びその使用方法
AR056574A1 (es) 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
MX2008013459A (es) 2006-04-20 2008-10-30 Amgen Inc Composiciones de anticuerpos glucagon/compuesto de peptido 1 similar al glucagon (glp-1).
CL2007002668A1 (es) 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
KR20200123866A (ko) 2007-02-09 2020-10-30 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
AR070844A1 (es) 2008-03-27 2010-05-05 Lilly Co Eli Fragmento fab o anticuerpo monoclonal humanizado que comprende el fragmento fab, y su uso para la manufactura de un medicamento antagonista del polipeptido del receptor de glucagon para el tratamiento o prevencion de diabetes de tipo 1 o 2
WO2009140342A1 (en) 2008-05-16 2009-11-19 Schering Corporation Glucagon receptor antagonists, compositions, and methods for their use
EP2346830B1 (en) 2008-09-15 2015-05-13 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8445538B2 (en) 2008-12-19 2013-05-21 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds
WO2010088061A1 (en) 2009-01-28 2010-08-05 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8324384B2 (en) 2009-02-12 2012-12-04 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010098948A1 (en) 2009-02-13 2010-09-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containin such compounds and methods of use
US8318667B2 (en) 2009-02-25 2012-11-27 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP2012188352A (ja) 2009-07-13 2012-10-04 Dainippon Sumitomo Pharma Co Ltd ３−（４−置換アルキル−フェニル）−２−フランカルボン酸誘導体およびその薬学的に許容される塩
FR2959129B1 (fr) * 2010-04-21 2013-02-01 Lucane Pharma Particules comprenant du 4-phenylbutyrate de sodium, procede de preparation et utilisations
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
EP3263102A1 (en) * 2011-09-30 2018-01-03 Horizon Therapeutics, LLC Methods of therapeutic monitoring of nitrogen scavenging drugs
EP2785740A1 (en) 2011-12-02 2014-10-08 Eli Lilly and Company Anti-glucagon antibodies and uses thereof
CN107001461A (zh) 2014-09-16 2017-08-01 瑞泽恩制药公司 抗胰高血糖素抗体及其使用方法

Similar Documents

Publication Publication Date Title
JP2023182691A5 (https=)
JP2024016177A5 (https=)
JP7551822B2 (ja) 治療用抗体製剤
RU2006120950A (ru) Антитело к cd40: препарат и способы
WO2021083271A1 (zh) 含有抗pd-l1抗体的稳定制剂
KR102039198B1 (ko) 악액질 치료법
JP2024531151A5 (https=)
CN114762678B (zh) 抗tigit抗体药物组合物及其用途
JP7398958B2 (ja) 安定的抗ｏｓｍｒ抗体製剤
JP2022121658A (ja) アミロイドーシスを処置するための組成物
TWI860741B (zh) Pvrig/tigit雙特異性抗體藥物組合物及其用途
JP2020531532A5 (https=)
HRP20160302T1 (hr) Monoklonska protutijela protiv feroportina 1 i njihova upotreba
JP7781519B2 (ja) グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法
US20190322734A1 (en) Treatment paradigm
JP2021533142A5 (https=)
EP3703819A1 (en) Method of treating tendinopathy using interleukin-17 (il-17) antagonists
KR20250079929A (ko) 항-FcRN 항체를 이용한 그레이브스병의 치료 방법
KR20250011948A (ko) 인터류킨-17(il-17) 길항제를 사용하여 건병증을 선택적으로 치료하는 방법
RU2824627C2 (ru) Фармацевтическая композиция анти-cd20 антитела и ее применение
US20240238272A1 (en) Treatment of antiphospholipid syndrome using s-hydroxychloroquine
US20250340643A1 (en) Anti-CTLA Antibody Compositions and Related Methods
RU2025126086A (ru) Композиции, содержащие биспецифическое антитело к gprc5d/cd3
RU2025129547A (ru) Способы применения мультиспецифических связывающих белков
HK40102408B (zh) 含抗lag-3抗体的药物组合物及其用途